A Study to Evaluate Luspatercept Utilization in Patients With Lower Risk Myelodysplastic Syndromes or Beta-thalassemia
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Terminated
Study type
Observational
Enrollment
30actual
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Insufficient enrollment
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-16 | actual | When the study began enrolling |
| Primary completion | 2025-05-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-01 | actual | The whole study's end, after follow-up |
| First posted | 2026-07-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Myelodysplastic Syndromes
- Beta-thalassemia
Intervention
- Drug: Luspatercept
Primary outcomes
what the primary-completion date above is the date OFParticipant age
measured Baseline
Participant gender
measured Baseline
Year of first luspatercept prescription
measured Baseline
Number of participants by Ring Sideroblast (RS) status (positive/negative/unknown) as measured by bone marrow aspiration
measured Baseline
Participant comorbidities
measured Baseline
Length of follow-up from start of luspatercept treatment initiation until the earliest of the end of continuous enrolment, death, or end of data availability
measured Baseline
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed